Protection from radiation nephropathy by WR-2721

Area of Science:

• Radioprotective agents
• Renal physiology
• Radiation oncology

Background:

• Radiation therapy can cause significant kidney injury, particularly in growing organs.
• Developing effective radioprotective strategies is crucial for improving patient outcomes in radiation oncology.
• The efficacy of WR-2721 (amifostine) in mitigating radiation-induced damage to the kidney has not been fully elucidated.

Purpose of the Study:

• To evaluate the efficacy of WR-2721 pretreatment in protecting the developing kidney against radiation injury.
• To assess the impact of WR-2721 on renal growth, function, and histology following irradiation.
• To determine the dose reduction factor for WR-2721-mediated renal protection.

Main Methods:

• Weanling mice underwent unilateral nephrectomy, followed by intraperitoneal injection of saline or WR-2721.
• The remaining kidney was irradiated with a single 1000-rad fraction.
• Renal growth, body weight, serum BUN, glomerular filtration rate, and renal histology were assessed at 3 and 24 weeks post-irradiation.

Main Results:

• WR-2721 pretreatment prevented radiation-induced renal growth inhibition and functional abnormalities (elevated BUN, reduced GFR).
• Non-irradiated WR-2721-treated animals showed normal growth and function.
• Histological examination revealed only mild radiation-compatible changes, with no clear correlation between protection and specific histologic findings.

Conclusions:

• WR-2721 effectively protects the growing kidney from radiation-induced injury, preserving both growth and function.
• The protective effect is not strongly correlated with specific histological changes observed within the study period.
• WR-2721 demonstrates potential clinical utility in enhancing renal radiation tolerance.